Announcements Trials

Browse Landscape

Status

Recruiting 2 Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Breast 3 Other hematologic neoplasm 2 Genitourinary 2 Tumor-Agnostic 1 Sarcoma 1 Other neoplasm 1 Other 1 Lymphoid 1 Head & Neck 1 Gynecologic 1 Gastrointestinal 1 Dermatologic 1 CNS 1

Conditions

Interventions

pembrolizumab 58 Cyclophosphamide 53 Ipilimumab 52 Nivolumab 44 aldesleukin 35 Interleukin-2 26 fludarabine phosphate 22 fludarabine 21 Vemurafenib 20 Temozolomide 19 Radiotherapy 18 dabrafenib 15 trametinib 12 Radiosurgery 11 CTLA-4 Antigen 11 Filgrastim 10 Dacarbazine 10 spartalizumab 9 cobimetinib 9 binimetinib 9 atezolizumab 9 Biopsy 9 poly ICLC 8 Paclitaxel 8 Antilymphocyte Serum 8 encorafenib 7 avelumab 7 Rituximab 7 Introns 7 romidepsin 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Exercise × Dermatologic × Clear all

NCT03464604 2022-11-23

Melanoma Accuracy Study; Phase 2

Nova Scotia Health Authority

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡